Comparative Pharmacology
Head-to-head clinical analysis: GENTAMICIN SULFATE versus U GENCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAMICIN SULFATE versus U GENCIN.
GENTAMICIN SULFATE vs U-GENCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
1-2 mg/kg IV every 8 hours or 3-5 mg/kg IV every 24 hours for extended-interval dosing; typical duration 7-10 days.
1-2 mg/kg IV every 8 hours for 7-10 days, targeting peak serum concentration of 6-10 mcg/mL and trough <2 mcg/mL.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged to 24-72 hours in renal impairment.
Terminal elimination half-life is 2-3 hours in patients with normal renal function; may prolong to 20-40 hours in end-stage renal disease
Renal excretion of unchanged drug accounts for >90% of elimination; biliary/fecal <2%.
Primarily renal (glomerular filtration) with 40-70% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%)
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic